G. Tartarelli

发表

Intensive post-operative follow-up of breast cancer patients with tumour markers: CEA, TPA or CA15.3 vs MCA and MCA-CA15.3 vs CEA-TPA-CA15.3 panel in the early detection of distant metastases

P. Ferrari, A. Nicolini, P. Miccoli, 2006, BMC Cancer.

Oral low-dose cyclophosphamide in metastatic hormone refractory prostate cancer (MHRPC).

P. Ferrari, A. Nicolini, A. Carpi, 2004, Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie.

Fulvestrant treatment is associated with cholesterol plasma level reduction in hormone receptor-positive metastatic breast cancer patients

O. Garrone, A. Sgambato, D. Amoroso, 2009, Cancer biology & therapy.

Long-term monitoring of cell-mediated immunity in disease-free breast cancer patients: a preliminary retrospective study.

P. Ferrari, A. Nicolini, P. Miccoli, 2002, Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie.

Sorafenib in a patient with advanced hepatocellular carcinoma and serious impairment of left ventricular function: a case report

D. Amoroso, M. Rondini, G. Tartarelli, 2009, Cases journal.

Ipsilateral right testicular metastasis from renal cell carcinoma in a responder patient to interleukine‐2 treatment

D. Amoroso, G. Tartarelli, A. Camerini, 2007, International journal of urology : official journal of the Japanese Urological Association.

Evaluation of HER2 and p53 expression in predicting response to docetaxel-based first-line chemotherapy in advanced breast cancer

P. Viacava, A. Cavazzana, D. Amoroso, 2011, Journal of experimental & clinical cancer research : CR.

Evaluation of HER 2 and p 53 expression in predicting response to docetaxel-based first-line chemotherapy in advanced breast cancer

P. Viacava, A. Cavazzana, D. Amoroso, 2011 .

Expression of dystroglycan correlates with tumor grade and predicts survival in renal cell carcinoma

G. Rossi, G. Genovese, A. Cittadini, 2007, Cancer biology & therapy.

First line chemotherapy with planned sequential administration of gemcitabine followed by docetaxel in elderly advanced non-small-cell lung cancer patients: a multicenter phase II study

E. Vasile, C. Tibaldi, A. Falcone, 2008, British Journal of Cancer.

Metronomic oral vinorelbine as first-line treatment in elderly patients with advanced non-small cell lung cancer: results of a phase II trial (MOVE trial)

D. Amoroso, G. Tartarelli, A. Camerini, 2015, BMC Cancer.

First-line treatment of NSCLC with bevacizumab: real world data from an Italian regional based survey

A. Chella, F. di Costanzo, F. Mazzoni, 2017, Journal of chemotherapy.

Phase II trial of single-agent oral vinorelbine in elderly (> or =70 years) patients with advanced non-small-cell lung cancer and poor performance status.

F. di Costanzo, F. Mazzoni, D. Amoroso, 2010, Annals of oncology : official journal of the European Society for Medical Oncology.

Metronomic oral vinorelbine as first-line treatment in elderly patients with advanced non-small cell lung cancer: results of a phase II trial (MOVE trial)

D. Amoroso, G. Tartarelli, A. Camerini, 2015, BMC Cancer.